Sprint Bioscience

27/03/2026

Sprint Bioscience are pleased to announce that groundbreaking findings from our DCPS program have once again been published, this time in the scientific journal Discover Oncology from Springer Nature. https://link.springer.com/article/10.1007/s12672-026-04880-x

“The new findings provide strong support for DCPS inhibition and clearly show how FHIT and IDH2 can be used to identify the patients who stand to benefit the most from DCPS-targeted treatment,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.

The article is a collaboration between Sprint Bioscience AB (publ), NeoTargets AB, and research groups led by Dr. Julian Walfridsson and Magnus Tobiasson at Karolinska Institutet. It has been partially funded by the Swedish Foundation for Strategic Research Stiftelsen för strategisk forskning, SSF through an industrial PhD fellowship.

Read the full press release here▪️https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-publishes-new-research-findings-that-strengthen-the-potential-of-dcps-inhibitors-in-aml

24/03/2026

We’re excited to share that our company is featured in Science Sweden!
Being highlighted by one of the leading media in the Nordic life science community is a proud moment for our team. The article showcases our continued commitment to advancing innovative drug discovery and contributing to the development of future therapies. A few key takeaways from the feature:

🟣 Recognition of our scientific approach and dedication to early‑stage drug development.

🟣 Spotlight on how our technology and methods can contribute to new treatment opportunities for cancer.

🟣 Acknowledgment of our team’s hard work and forward‑looking mindset.

▪️ Read the full article here (for now only available in Swedish): https://www.lifesciencesweden.se/article/view/1218102/sprint_bioscience_bygger_molekylerna_som_ska_bli_nya_lakemedel

We’re grateful for the visibility and inspired to keep pushing the boundaries of what’s possible.

20/03/2026

We are proud to share that our teams continue to deliver important scientific progress across our portfolio. Following the recently presented in vivo data from our glioblastoma program, we are now preparing to unveil new preclinical results in acute myeloid leukaemia (AML) at the AACR Annual Meeting in April.
To discuss these advancements, our Chief Scientific Officer Martin Andersson joined the BioStock - Connecting Innovation & Capital studio for an interview.
Watch the full conversation: https://biostock.se/en/2026/03/positiva-data-och-kommande-presentationer-sprint-biosciences-cso-berattar-mer/

Watch the whole interview with CSO Martin Andersson here.

18/03/2026

Sprint Bioscience presents new preclinical data from the company’s DCPS research program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. 🟣https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-presents-new-preclinical-data-on-dcps-at-the-aacr-annual-meeting-2026

The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.

The AACR Annual Meeting is one of the world’s most prominent scientific conferences in cancer research, bringing together leading researchers, clinicians, and drug developers. More information about the conference is available on AACR’s official website: https://www.aacr.org/meeting/aacr-annual-meeting-2026/


▪️ Subscribe for future press releases https://sprintbioscience.com/en/subscribe/

17/03/2026

Sprint Bioscience today announces positive results from a pre-clinical proof-of-concept (POC) study performed within our VRK1 program. The results show that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected. This confirms the tumor‑specific mechanism of the program and demonstrates that VRK1 is a relevant target for the treatment of VRK2‑low glioblastoma.

“We are thrilled to report a positive outcome from this POC study. These results provide pharmacological validation of VRK1 as a relevant target in glioblastoma. To our knowledge, this is the first demonstration of anti-tumor effects from selective VRK1 inhibition in vivo. We look forward to presenting these results at upcoming partnering conferences,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.
🟣https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-reports-positive-results-from-the-vrk1-program

11/03/2026

At Sprint Bioscience, we are proud to attend, through our CEO Johan Emilsson, Cancerfonden’s 75th Anniversary Gala, an evening that honors the type of research that forms the foundation of tomorrow’s medicines. 💜

As a research‑driven company, our work is built in part on the fundamental research and discoveries that, among other things, are made possible by Cancerfonden. Since 1951, the foundation has contributed SEK 17 billion to Swedish cancer research. Thanks to long‑term commitments and the relentless efforts of scientists, seven out of ten people diagnosed with cancer survive today, compared with three out of ten when Cancerfonden was founded. These advances are the result of researchers who never give up, and without their tireless work, our company would not exist.

We are grateful for the invitation and for the opportunity to share the evening with those who push fundamental research forward, every single day.

16/01/2026

Do you breathe science?
Do you thrive in the lab?
Do you want to work in an efficient and multidisciplinary research environment?

We are now looking for someone who shares our passion for laboratory work in cell biology to become a part of our Tumor Biology and Therapeutics team. Apply today!🔗https://sprintbioscience.com/en/career/

14/01/2026

Sprint Bioscience reports from San Francisco and the J.P. Morgan Healthcare Week. BioStock caught up with CEO Johan Emilsson, who is on-site amidst the buzz. He notes a clear interest in our company’s early-stage drug development programs and the 2025 agreement has served as a strong mark of quality. It has not only validated our technology platform but also opened doors to new connections and increased interest across the entire portfolio.

🎥 Watch the video interview here: https://biostock.se/2026/01/sprint-bioscience-pa-j-p-morgan-healthcare-week/

19/12/2025

Sprint Bioscience, represented by CEO Johan Emilsson, is attending JPM Week 2026 in San Francisco, January 12–15.

is the flagship gathering of the year for the global life science community – a full week of partnering, investor meetings, and groundbreaking ideas. We’re ready to showcase what’s next in oncology innovation.

We look forward to presenting Sprint Bioscience’s cutting-edge programs and exploring strategic collaborations that accelerate cancer drug development.

📍 Interested in connecting? Reach out via https://letspartner.bio.org/ Let’s discuss how we can partner!

25/11/2025

Sprint Biosciene CEO, Johan Emilsson, was invited to EFN Ekonomikanalen to discuss the transformative agreement with Gilead Sciences, where Sprint Bioscience divested its cancer program TREX1.

This deal is a strong validation of our world-class research and a significant step forward, not just for Sprint Bioscience, but for the entire Swedish industry.

Johan shared insights on what this partnership means for our pipeline and how it positions Sprint Bioscience for continued growth and innovation in oncology drug discovery.

🎥 Watch the full interview on EFN (in Swedish): https://efn.se/play/sprint-rusar-efter-affaren-med-gilead-det-hander-nu

Sprint rusar efter affären med Gilead – det händer nu| Håll dig uppdaterad med aktuella ekonominyheter – gratis.

24/11/2025

Sprint Bioscience today announced the sale of our TREX1 cancer program to Gilead Sciences, Inc. The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.
“We are pleased to enter into this agreement with Gilead, whom we value highly as a business partner. We appreciate their forward-looking approach and strong commitment to cutting-edge pharmaceutical development. TREX1 has demonstrated significant potential in the pre-clinical phase, and our decision to sell the program, rather than license it, reflects a strategic shift toward more flexible, value-driven exit opportunities,” said Emilsson, CEO of Sprint Bioscience.
Press release to be found here➡️
English: https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-sells-the-trex1-program-to-gilead
Swedish: https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-saljer-trex1-programmet-till-gilead

14/10/2025

Sprint Bioscience is pleased to be in Gothenburg for Nordic Life Science Days – a key meeting point where innovation, partnerships, and the future of health take center stage. Our CEO Johan Emilsson and CSO Martin Andersson are on site, engaging in one-to-one meetings and discussions that help shape the next chapter in life science.

A special thank you to the Flemingsberg team Life Science Cluster Flemingsberg & Stiftelsen Flemingsberg Science for hosting us in their vibrant and welcoming booth (complete with a selfie machine 📸) – a space that truly reflects the energy and creativity of the region. Flemingsberg, Huddinge, is where we have our labs and conduct our everyday work. 🧪 🔬 🧫 💻
Last but not least - thank you SwedenBIO for a well-executed event.